Biotech stocks are in focus as analysts track upcoming clinical data and regulatory decisions in autoimmune and rare disease ...
Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced.
Rapport Therapeutics, Inc., a clinical-stage biotechnology company focused on developing precision medicines for neurological and psychiatric disorders, is hosting its first Investor and Analyst Day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results